Center-Authored Papers

Filters: Author is Vose, Julie M  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM et al..  2005.  Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.. Blood. 105(12):4576-82. Abstract
Maziarz RT, Wang Z, Zhang M-J, Bolwell BJ, Chen AI, Fenske TS, Freytes CO, Gale RP, Gibson J, Hayes-Lattin BM et al..  2013.  Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement.. British journal of haematology. 162(5):648-56. Abstract
C
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Czuczman MS, Fayad LE et al..  2015.  Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(3):326-62. Abstract
D
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Fayad LE, Fisher RI et al..  2016.  Diffuse Large B-Cell Lymphoma Version 1.2016.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(2):196-231. Abstract
E
Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen Y-B et al..  2014.  Early Failure of Frontline Rituximab-containing Chemoimmunotherapy in Diffuse Large B-Cell Lymphoma does not Predict Futility of Autologous Hematopoietic Cell Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
G
Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ et al..  2015.  Gray zone lymphoma with features intermediate between classical hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort.. American journal of hematology. Abstract
I
Tefferi A, Kantarjian H, Rajkumar VS, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC et al..  2015.  In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.. Mayo Clinic proceedings.
L
Evens AM, Advani R, Press OW, Lossos IS, Vose JM, Hernandez-Ilizaliturri FJ, Robinson BK, Otis S, Nadav Dagan L, Abdallah R et al..  2013.  Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(32):4132-9. Abstract
M
Hosein PJ, Maragulia JC, Salzberg MP, Press OW, Habermann TM, Vose JM, Bast M, Advani RH, Tibshirani R, Evens AM et al..  2014.  A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.. British journal of haematology. 165(3):358-63. Abstract
N
Anderson KC, Alsina M, Bensinger WI, Biermann SJ, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA et al..  2009.  NCCN clinical practice guidelines in oncology: multiple myeloma.. Journal of the National Comprehensive Cancer Network : JNCCN. 7(9):908-42.
Zelenetz AD, Abramson JS, Advani RH, Andreadis BC, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP et al..  2010.  NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.. Journal of the National Comprehensive Cancer Network : JNCCN. 8(3):288-334.
Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Caimi P, Fayad LE et al..  2017.  NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017.. Journal of the National Comprehensive Cancer Network : JNCCN. 15(3):293-311. Abstract
Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Fayad LE et al..  2016.  NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(9):1067-79. Abstract
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE et al..  2013.  Non-Hodgkin's lymphomas, version 1.2013.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(3):257-72;quiz273. Abstract
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS et al..  2014.  Non-Hodgkin's Lymphomas, Version 2.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(6):916-46. Abstract
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L et al..  2012.  Non-Hodgkin's Lymphomas, version 3.2012.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(12):1487-98. Abstract
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Czuczman MS, Fayad LE et al..  2014.  Non-Hodgkin's lymphomas, version 4.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(9):1282-303. Abstract
Zelenetz AD, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ et al..  2011.  Non-Hodgkin's lymphomas.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(5):484-560.
O
Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros JL et al..  2017.  Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2017722157. Abstract
P
Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B et al..  2016.  A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.. British journal of haematology. 172(4):535-544. Abstract
Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, Stadtmauer EA, Mineshi S, Ambinder R, Fenske T et al..  2013.  Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT C. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(13):1662-8. Abstract
R
Perales M-A, Ceberio I, Armand P, Burns LJ, Chen R, Cole PD, Evens AM, Laport GG, Moskowitz CH, Popat U et al..  2015.  Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(6):971-983. Abstract
S
Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT et al..  2013.  Salvage Second Hematopoietic Cell Transplantation in Myeloma.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
Landsburg DJ, Falkiewicz MK, Petrich AM, Chu BA, Behdad A, Li S, Medeiros JL, Cassaday RD, Reddy NM, Bast MA et al..  2016.  Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.. British journal of haematology. 175(4):631-640. Abstract
T
Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih C-J, Williams MP, Shaffer AL, Gerecitano J et al..  2015.  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.. Nature medicine. Abstract